
    
      This study is designed to evaluate the efficacy and tolerability of brentuximab vedotin as
      monotherapy and in combination with other agents as frontline therapy. There are 6 parts of
      the study. The population to be studied includes treatment-naïve patients with classical
      Hodgkin lymphoma (HL) or treatment-naïve patients with CD30-expressing peripheral T-cell
      lymphoma (PTCL).
    
  